title: The NCI60 human tumour cell line anticancer drug screen.
abstract: The US National Cancer Institute (NCI) 60 human tumour cell line anticancer drug screen (NCI60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumours in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumour-cell kill. Recently, its role has changed to that of a service screen supporting the cancer research community. Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy.
authors.affiliation: Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702-1201, USA. shoemaker@dtpax2.ncifcrf.gov
authors.forename: Robert H
authors.initials: RH
authors.lastname: Shoemaker
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000266:history / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor / Q000266:history*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D009316:National Institutes of Health (U.S.) / Q000266:history / Q000458:organization & administration; D014407:Tumor Cells, Cultured; D014481:United States
chemical_list: D000970:Antineoplastic Agents